Hepatocellular carcinoma (HCC) has emerged as a major cause of cancer-related death. Its
mortality has increased in Western populations, with a minority of patients diagnosed at …

Mortality owing to liver cancer has increased in the past 20 years, and the latest estimates
indicate that the global health burden of this disease will continue to grow. Most patients with …

Sorafenib, an orally-available kinase inhibitor, is the only standard clinical treatment against
advanced hepatocellular carcinoma. However, development of resistance to sorafenib has …

Genomic profiling of hepatocellular carcinoma (HCC) tumors has elucidated recurrent
molecular aberrations common or specific to disease etiology, patient race or geographic …

Hepatocellular carcinoma (HCC) is an aggressive tumor and the sixth most common form of
cancer worldwide. Surgery is the gold-standard treatment for local disease and often …

Sorafenib is the only and standard systematic chemotherapy drug for treatment of advanced
hepatocellular carcinoma (HCC) at the current stage. Although sorafenib showed survival …

Liver cancer has become the second cause of cancer-related death worldwide. Most
patients are still diagnosed at intermediate or advanced stage, where potentially curative …

Introduction: Sorafenib is the only systemic drug approved for the treatment of advanced
hepatocellular carcinoma (HCC). Within recent years, several investigational agents mainly …

Hepatocellular carcinoma (HCC) is a major health problem. Mortality owing to liver cancer
has increased in the past 20 years, with recent studies reporting an incidence of 780,000 …

Sorafenib is the only approved systemic treatment for advanced hepatocellular carcinoma
patients and all the recently published randomized controlled trials on new systemic drugs …